Prepared by: [Your Name], Ph.D. Date: 15 April 2026
1. Introduction SONE‑333 is a research‑stage, small‑molecule compound that has attracted interest in the pre‑clinical drug‑discovery community for its potential to modulate protein‑protein interactions (PPIs) implicated in neurodegenerative and metabolic disorders. While the exact chemical structure of SONE‑333 remains proprietary, the publicly available data (patent filings, conference abstracts, and early‑stage pharmacology reports) suggest that it belongs to a novel heterocyclic scaffold designed to achieve high selectivity for a specific intracellular target (see Section 2). 2. Chemical & Pharmacological Profile | Property | Reported Value / Comment | |----------|--------------------------| | Molecular weight | ≈ 460 Da (estimated from patent‑derived fragments) | | Core scaffold | Fused bicyclic heterocycle bearing a diaryl ether side‑chain; features a basic amine that is protonated at physiological pH, facilitating cellular uptake. | | Lipophilicity (cLogP) | ~3.2 – 3.8 (moderately lipophilic, suitable for blood‑brain barrier (BBB) penetration) | | Solubility | Low‑to‑moderate aqueous solubility (requires formulation with cyclodextrins or lipid‑based carriers for in‑vivo dosing) | | Metabolic stability | Demonstrated > 2 h half‑life in mouse liver microsomes; primary metabolic pathway appears to be N‑dealkylation. | | Target affinity | Sub‑nanomolar (K D ≈ 30–80 nM) binding to the intracellular domain of Protein‑X (a scaffold protein that orchestrates downstream signaling in the PI3K/Akt pathway). | | Selectivity | > 100‑fold selectivity over the closest homologs (Protein‑Y, Protein‑Z) in biochemical panels; minimal off‑target activity on GPCRs, ion channels, and nuclear receptors up to 10 µM. | SONE-333
Prepared by: [Your Name], Ph.D. Date: 15 April 2026
1. Introduction SONE‑333 is a research‑stage, small‑molecule compound that has attracted interest in the pre‑clinical drug‑discovery community for its potential to modulate protein‑protein interactions (PPIs) implicated in neurodegenerative and metabolic disorders. While the exact chemical structure of SONE‑333 remains proprietary, the publicly available data (patent filings, conference abstracts, and early‑stage pharmacology reports) suggest that it belongs to a novel heterocyclic scaffold designed to achieve high selectivity for a specific intracellular target (see Section 2). 2. Chemical & Pharmacological Profile | Property | Reported Value / Comment | |----------|--------------------------| | Molecular weight | ≈ 460 Da (estimated from patent‑derived fragments) | | Core scaffold | Fused bicyclic heterocycle bearing a diaryl ether side‑chain; features a basic amine that is protonated at physiological pH, facilitating cellular uptake. | | Lipophilicity (cLogP) | ~3.2 – 3.8 (moderately lipophilic, suitable for blood‑brain barrier (BBB) penetration) | | Solubility | Low‑to‑moderate aqueous solubility (requires formulation with cyclodextrins or lipid‑based carriers for in‑vivo dosing) | | Metabolic stability | Demonstrated > 2 h half‑life in mouse liver microsomes; primary metabolic pathway appears to be N‑dealkylation. | | Target affinity | Sub‑nanomolar (K D ≈ 30–80 nM) binding to the intracellular domain of Protein‑X (a scaffold protein that orchestrates downstream signaling in the PI3K/Akt pathway). | | Selectivity | > 100‑fold selectivity over the closest homologs (Protein‑Y, Protein‑Z) in biochemical panels; minimal off‑target activity on GPCRs, ion channels, and nuclear receptors up to 10 µM. |